Realcan Pharmaceutical Group Co (SZSE:002589) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:002589 Realcan Pharmaceutical Group Co Ltd SZSE:002589
50 GF Score
Price ¥3.53
GF Value ¥2.35
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Realcan Pharmaceutical Group Co FFO?

FFO (Funds from operations) only applies to REITs.

SZSE:002589
50GF Score
Realcan Pharmaceutical Group Co Ltd SZSE:002589
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Realcan Pharmaceutical Group Co (SZSE:002589) Overvalued in 2026?

Based on GuruFocus' analysis, Realcan Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥3.53 is trading 50.2% above its estimated GF Value™ of ¥2.35. GuruFocus considers Realcan Pharmaceutical Group Co to be Significantly Overvalued.

Key valuation signals for SZSE:002589:

  • FFO:
  • GF Value™: ¥2.35 vs. price of ¥3.53 (50.2% above fair value)
  • GF Score™: 50/100 with 9 warning signs

No single metric tells the full story. See the SZSE:002589 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Realcan Pharmaceutical Group Co Business Description

Address No. 326, Airport Road, Zhifu District, Shandong Province, Yantai, CHN, 264004
Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.
50GF Score

Get the complete analysis for SZSE:002589

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥3.53
Price
¥2.35
GF Value